- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02299999
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (SAFIR02_Breast)
PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
- Drug: AZD2014
- Drug: AZD4547
- Drug: AZD5363
- Drug: AZD8931
- Drug: Selumetinib
- Drug: Vandetanib
- Drug: Bicalutamide
- Drug: Olaparib
- Drug: Anthracyclines
- Drug: Taxanes
- Drug: cyclophosphamide
- Drug: DNA intercalators
- Drug: Methotrexate
- Drug: vinca alkaloids
- Drug: Platinum based chemotherapies
- Drug: Bevacizumab
- Drug: Mitomycin C
- Drug: Eribulin
- Drug: MEDI4736
Detailed Description
Screening phase:
New frozen biopsy or an archived frozen sample or ctDNA sample will be sent to the genomic platforms for DNA extraction and genomic analysis (DNA microarrays and Next generation sequencing).
Patients can be considered as pre-eligible for the targeted substudy 1 randomisation phase when both following mandatory conditions have been met: stable or responding disease has been observed (investigator judgment) after 6 to 8 cycles of chemotherapy (or at least after 4 cycles of chemotherapy if stopped for toxicity) and targetable alteration has been identified by the Molecular Tumor Board (MTB).
If not eligible for the substudy 1 randomisation phase, patients can be considered as pre-eligible for the immune substudy 2 randomization phase when both following mandatory conditions are met: stable or responding disease (investigator judgment) is observed after 6 to 8 cycles of chemotherapy (or at least after 4 cycles if treatment was stopped due to toxicity) AND not eligible to randomization in the substudy 1 (because patient had no targetable alteration identified by the Molecular Tumor Board, or failed to have a genomic profile for the tumor [low tumor cells percentage, technical issue during genomic analysis, etc.], or a non inclusion criteria that precluded entry into the substudy 1)
Randomization phase:
The mandatory post-chemotherapy wash-out period, of 28 days for 21 or 28 day-cycle chemotherapies or of 15 days for weekly (except monoclonal antibodies) or daily chemotherapies,will provide time to achieve all the required tests and examinations.
The randomization program will allocate the following treatments with a 2:1 ratio in favor of Arm A of the considered substudy:
Substudy 1 : targeted therapies versus standard maintenance chemotherapy
- Arm A1 / targeted arm: targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, or
- Arm B1 / chemotherapy arm : maintenance chemotherapy (or no antineoplastic treatment in case of toxicity at the time of randomization)
Substudy 2 : immunotherapy versus standard maintenance chemotherapy
- Arm A2 / immunotherapy maintenance arm: MEDI4736 or
- Arm B2 / chemotherapy arm: chemotherapy continued as a maintenance chemotherapy (or no antineoplastic treatment in case of toxicity)
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Angers, France
- Institut de Cancérologie de l'Ouest/Paul Papin
-
Avignon, France
- Institut Sainte-Catherine
-
Bordeaux, France
- Institut Bergonié
-
Bordeaux, France, 33077
- Polyclinique Bordeaux Nord Aquitaine
-
Caen, France
- Centre Francois Baclesse
-
Clermont-Ferrand, France
- Centre Jean Perrin
-
Dijon, France, 21079
- Centre Georges Francois Leclerc
-
La Roche-sur-Yon, France, 85925
- CHD Vendée
-
Lille, France
- Centre Oscar Lambret
-
Limoges, France, 87000
- Chu Dupuytren
-
Lyon, France
- Centre Leon Berard
-
Lyon, France
- Centre Hospitalier Lyon Sud
-
Marseille, France
- Institut Paoli Calmettes
-
Montpellier, France
- Institut Régional du Cancer Montpellier Val d'Aurelle
-
Nancy, France
- Centre Alexis Vautrin
-
Nantes, France
- Institut de Cancérologie de l'Ouest/ René Gauducheau
-
Nice, France
- Centre Antoine Lacassagne
-
Paris, France
- Institut Curie
-
Rennes, France
- Centre Eugene Marquis
-
Rouen, France
- Centre Henri Becquerel
-
Saint-Cloud, France
- Institut Curie
-
Strasbourg, France
- Hopitaux universitaire de strasbourg - Hopital civil
-
Thonon-les-Bains, France, 74200
- Hôpitaux du Léman
-
Toulouse, France
- Institut Claudius Regaud
-
Villejuif, France
- Gustave Roussy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Screening phase:
Inclusion Criteria:
- Women (or men) with histologically proven breast cancer
- Metastatic relapse or progression or stage IV at diagnosis
- No Her2 over-expression
- Patients with metastases that can be biopsied, except bone metastases
- Patients who are eligible for a first or a second line of chemotherapy in metastatic setting (left to the discretion of investigators), or who are currently treated with a first or second line of chemotherapy with a maximum of 2 cycles at the time of biopsy. Screening of patients currently treated with a second line chemotherapy should have a stable disease
- For patients with ER+ disease, relapse or progression occurred during endocrine therapy, whatever the line, or less than 12 months after the end of endocrine therapy in adjuvant context
- Age ≥18 years
- WHO Performance Status 0/1
- Presence of measurable target lesion according to RECIST criteria v1.1
Exclusion criteria:
- Spinal cord compression and/or symptomatic or progressive brain metastases
- Bone metastases when this is the only site of biopsiable disease
- Patients with all target lesions in a previously irradiated region, except if clear progression has been observed prior to study in at least one of them
- Patient who received more than 2 lines of chemotherapy at the time of the biopsy
- Tumor progression observed with the current line of treatment when under 2nd line
- Patients who already had a genomic profile (both CGH and NGS analysis) in which no SAFIR02 targetable alterations have been identified
- Abnormal coagulation contraindicating biopsy
- Inability to swallow
- Major problem with intestinal absorption Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG Any factors increasing the risk of QTc prolongation or arrhythmic events Experience of any of the following in the preceding 12 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, past or current uncontrolled angina pectoris, congestive heart failure NYHA Grade ≥2, torsades de pointes, current uncontrolled hypertension, cardiomyopathy Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which requires steroid treatment or any evidence of clinically interstitial lung disease Previous or current malignancies of other histologies within the last 5 years, Evidence of severe or uncontrolled systemic disease (active bleeding diatheses, or active Hepatitis B, C and HIV)
- diagnosis of acne rosacea, severe psoriasis and severe atopic eczema
- Prior exposure to anthracyclines or mitoxantrone with cumulative exposure in excess of 360 mg/m² for doxorubicin, 720 mg/m² for epirubicin, or 72 mg/m² for mitoxantrone
- Previous treatment with the same agent or in the same class as one of those used in the SAFIR02 trial (patients who received this previous targeted agent without the target prescreening are eligible but may not be eligible for randomisation in substudy 1 if the treatment allocated by the MTB is in the same class) History of retinal degenerative disease, eye injury or corneal surgery in the previous 3 months, past history of central serous retinopathy or retinal vein occlusion, intraocular pressure >21 mmHg, or uncontrolled glaucoma.
- History of hemorrhagic or thrombotic stroke, TIA or other CNS bleeds
- Renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome, renal tubular acidosis
- Patients using drugs that are known potent inhibitors or potent inducers or substrates of cytochrome P450
Randomized phase:
Substudy 1:
Inclusion Criteria:
- Patients who received 6 to 8 cycles of chemotherapy, or having received at least 4 cycles of chemotherapy definitively stopped for toxicity reasons, and who are presenting a SD or PR at randomization
- presenting at least one genomic alteration from the predefined list
- Age ≥25 years for patients planned to receive AZD4547
- 28-day wash-out period from chemo prior to randomization and grade ≤1 residual toxicities
Exclusion Criteria:
- More than 2 previous lines of chemotherapy for metastatic disease before randomization
- Life expectancy <3 months
- Disease progression occuring at any time during chemotherapy and before randomization or toxicity that led to the discontinuation of the last chemotherapy before 4 full cycles have been delivered
- Less than 28 days from radiotherapy, less than 2 weeks from palliative radiation
- Patients previously treated with a targeted agent in the same class as the agent to be given to the patient in substudy 1
- Toxicities of grade ≥2 from any previous anti-cancer therapy
- Altered haematopoietic or organ function
- Mean resting corrected QT interval (QTc) >480 msec (or QTcF >450 msec) obtained from 3 consecutive ECGs
- Left ventricular ejection fraction (LVEF) <55% (MUGA scan or Echocardiogram)
- Altered ophthalmic conditions confirmed by an ophthalmology specialist for patients likely to be treated with AZD4547 orAZD8931 or Selumetinib
- Patients using non-substitutable drugs, that are known to prolong QT interval or induce Torsades de Pointes, when they are supposed to be treated with vandetanib, AZD5363 or AZD8931
Substudy 2:
Inclusion Criteria:
- Patients who received 6 to 8 cycles of chemotherapy, or having received at least 4 cycles of chemotherapy definitively stopped for toxicity reasons, and who are presenting a SD or a RP at randomization
- Patients not eligible to substudy 1
- wash-out period of at least 15 days for weekly (except monoclonal antibodies) or daily chemotherapies or 28 days for other chemotherapies from last chemotherapy administration prior to randomization and grade ≤1 residual toxicities
Exclusion Criteria:
- More than 2 previous lines of chemotherapy for metastatic disease before randomization
- Life expectancy <3 months
- Disease progression occuring at any time during chemotherapy and before randomization or toxicity that led to the discontinuation of the last chemotherapy before 4 full cycles have been delivered
- Any previous treatment with a PD1 or PD-L1 inhibitor, including MEDI4736
- Toxicities of grade ≥2 from any previous anti-cancer therapy
- Altered haematopoietic or organ function
- Mean resting QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 consecutive ECGs using Bazett's Correction
- Current or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
- Active or prior documented autoimmune disease within the past 2 years NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded
- History of primary immunodeficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Substudy 1: targeted agent
Arm A1 / Targeted Arm : targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, bicalutamide tablet per os 150 od, continuous dosing, olaparib tablet per os 300 mg bd, continuous dosing
|
Target: m-TOR
Target: EGFR
Target: AKT
Target: HER2, EGFR
Target: MEK
Other Names:
Target: VEGF, EGFR
Other Names:
target: Androgen receptor
Other Names:
Target: PARP
Other Names:
|
Active Comparator: Substudy 1: standard maintenance therapy
Arm B1/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
|
DNA intercalation
Other Names:
Target: mitotic tubulin and microtubules
Other Names:
Alkylating agents
Other Names:
DNA intercalators
Other Names:
DNA intercalators
Target: mitotic tubulin and microtubules
Other Names:
Platinum based chemotherapies
Other Names:
Target: VEGF
Other Names:
Alkylating agents
Other Names:
Microtubule modulator
Other Names:
|
Experimental: Substudy 2: Immunotherapy
Arm A2/ Immunotherapy arm: maintenance with MEDI4736 for patient without actionable genomic alterations or non eligible to Targeted substudy 1, MEDI4736 Intra-venous 10 mg/kg, Q2W
|
Target: PD-L1
|
Active Comparator: Substudy 2: standard maintenance therapy
Arm B2/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
|
DNA intercalation
Other Names:
Target: mitotic tubulin and microtubules
Other Names:
Alkylating agents
Other Names:
DNA intercalators
Other Names:
DNA intercalators
Target: mitotic tubulin and microtubules
Other Names:
Platinum based chemotherapies
Other Names:
Target: VEGF
Other Names:
Alkylating agents
Other Names:
Microtubule modulator
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm
Time Frame: from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
|
To evaluate whether treatment with targeted agents guided by high throughput molecular analysis (CGH array, next generation sequencing) improves progression-free survival as compared to standard maintenance therapy in patients with metastatic Breast Cancer
|
from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression-free survival in patients treated with anti-PDL1 antibody (MEDI4736) compared to standard maintenance therapy arm
Time Frame: from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
|
To evaluate whether treatment with MEDI4736 improves progression-free survival as compared to standard maintenance therapy in patients with metastatic Breast Cancer
|
from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
|
overall survival in each substudy
Time Frame: from randomization to death (any cause), up to 16 months
|
To evaluate whether treatment with targeted agents guided by high throughput molecular analysis (CGH array, next generation sequencing) or MEDI4736 improves overall survival as compared to standard maintenance therapy in patients with metastatic Breast Cancer
|
from randomization to death (any cause), up to 16 months
|
overall response rates and changes in tumor size in each substudy
Time Frame: tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
|
tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria
|
tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
|
evaluate safety, in each substudy
Time Frame: toxicities will be assessed during the whole treatment period (4 months expected in average) followed by a 1-year post-treatment follow-up period, and reported during the visits scheduled by the study flow chart
|
Toxicities are graded according to the CTCAE V4
|
toxicities will be assessed during the whole treatment period (4 months expected in average) followed by a 1-year post-treatment follow-up period, and reported during the visits scheduled by the study flow chart
|
efficacy (response rate, change in tumor size, progression-free survival, overall survival) and safety of each individual targeted agent (substudy 1)
Time Frame: tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
|
tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria
|
tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
|
correlate molecular characteristics in patients with the efficacy endpoints (response rate, progression-free and overall survival) in each substudy
Time Frame: from randomization or treatment initiation to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
|
tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria
|
from randomization or treatment initiation to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fabrice ANDRE, Pr, Gustave Roussy, Villejuif
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dermatologic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Antibiotics, Antineoplastic
- Hormone Antagonists
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Androgen Antagonists
- Docetaxel
- Cyclophosphamide
- Carboplatin
- Cisplatin
- Olaparib
- Capecitabine
- Epirubicin
- Durvalumab
- Bevacizumab
- Doxorubicin
- Liposomal doxorubicin
- Vinorelbine
- Methotrexate
- Vincristine
- Bicalutamide
- Mitomycins
- Mitomycin
- Taxane
- Vinblastine
- Vinca Alkaloids
- Gemcitabine
Other Study ID Numbers
- UC-0105/1304
- 2013-001652-36 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on AZD2014
-
Samsung Medical CenterWithdrawn
-
Massachusetts General HospitalUnited States Department of Defense; AstraZenecaCompletedMeningioma | Neurofibromatosis 2United States
-
Massachusetts General HospitalNational Cancer Institute (NCI); AstraZenecaActive, not recruiting
-
Samsung Medical CenterAstraZenecaTerminatedSmall Cell Lung CancerKorea, Republic of
-
Samsung Medical CenterWithdrawnSolid TumorKorea, Republic of
-
AstraZenecaWithdrawnCore: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
-
Royal Marsden NHS Foundation TrustAstraZeneca; Institute of Cancer Research, United KingdomCompletedAdvanced CancerUnited Kingdom
-
Canadian Cancer Trials GroupAstraZenecaCompletedGlioblastoma MultiformeCanada
-
AstraZenecaActive, not recruiting
-
Samsung Medical CenterTerminatedCancer of StomachKorea, Republic of